Literature DB >> 2706326

Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

A von Rosen1, L E Rutqvist, J Carstensen, A Fallenius, L Skoog, G Auer.   

Abstract

The prognostic value of nuclear DNA distribution pattern in relation to tumor size, axillary lymph node status, and estrogen receptor (ER) content was studied in 464 patients with primary, operable mammary adenocarcinoma. The median follow-up time was 3 1/2 years. Slide cytophotometric DNA analysis was performed on morphologically identified Feulgen-stained tumor cells. The tumors were classified into four subgroups according to their DNA histogram type. DNA content was significantly related to tumor size and ER level but not to nodal status. When all variables were stimultaneously introduced into Cox's proportional hazards model, tumor size, nodal status, and DNA profile remained as significant predictors of recurrence. Restricting the analysis to node-negative patients, both DNA profile and tumor size showed a significant prognostic value. DNA did not contribute significant prognostic information in node-positive patients. However, the trends in recurrence-free survival were similar to those in the node-negative subgroup: patients with aneuploid tumors tended to fare worse than those with euploid carcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706326     DOI: 10.1007/BF01806547

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  42 in total

1.  Effects of repeated mammographic screening on breast cancer stage distribution. Results from a randomised study of 92 934 women in a Swedish county.

Authors:  G Fagerberg; L Baldetorp; O Gröntoft; B Lundström; J C Månson; B Nordenskjöld
Journal:  Acta Radiol Oncol       Date:  1985 Nov-Dec

2.  Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations.

Authors:  S B Ewers; E Långström; B Baldetorp; D Killander
Journal:  Cytometry       Date:  1984-07

3.  Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance.

Authors:  D W Hedley; M L Friedlander; I W Taylor
Journal:  Cytometry       Date:  1985-07

4.  The reliability of microspectrophotometric and flow cytometric nuclear DNA measurements in adenocarcinomas of the breast.

Authors:  A G Fallenius; U G Askensten; L K Skoog; G U Auer
Journal:  Cytometry       Date:  1987-05

5.  Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.

Authors:  J Harvey; N de Klerk; I Berryman; G Sterrett; M Byrne; J Papadimitriou
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

6.  Prognostic significance of the DNA content of human breast cancer.

Authors:  C S Dowle; A Owainati; A Robins; K Burns; I O Ellis; C W Elston; R W Blamey
Journal:  Br J Surg       Date:  1987-02       Impact factor: 6.939

7.  Image and flow cytometric analysis of DNA content in breast cancer. Relation to estrogen receptor content and lymph node involvement.

Authors:  C J Cornelisse; H R de Koning; A J Moolenaar; C J van de Velde; J S Ploem
Journal:  Anal Quant Cytol       Date:  1984-03

8.  Undernotification of diagnosed cancer cases to the Stockholm Cancer Registry.

Authors:  B Mattsson; L E Rutqvist; A Wallgren
Journal:  Int J Epidemiol       Date:  1985-03       Impact factor: 7.196

9.  DNA distribution, cytosol estrogen receptors and axillary nodes as prognostic predictors in breast carcinoma.

Authors:  C Klintenberg; A Wallgren; K Bjelkenkrantz; J Carstenssen; S Humla; B Nordenskjöld; L Skoog
Journal:  Acta Radiol Oncol       Date:  1985 May-Jun

10.  Prognostic significance of DNA measurements in 409 consecutive breast cancer patients.

Authors:  A G Fallenius; G U Auer; J M Carstensen
Journal:  Cancer       Date:  1988-07-15       Impact factor: 6.860

View more
  8 in total

Review 1.  Aneuploidy as a prognostic factor in breast cancer.

Authors:  A von Rosen
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Prognostic factors and natural history in lymph node-negative breast cancer patients.

Authors:  R Arriagada; L E Rutqvist; L Skoog; H Johansson; A Kramar
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  A retrospective study on the clinical and biological prediction of axillary lymph node metastasis in breast cancer.

Authors:  M Noguchi; N Ohta; M Thomas; H Kitagawa; M Earashi; I Miyazaki; Y Mizukami
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

4.  DNA ploidy and S-phase fraction in medullary carcinoma of the breast--a flow cytometric analysis using archival material.

Authors:  L Pedersen; J K Larsen; I J Christensen; A Lykkesfeldt; S Holck; T Schiødt
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Improved prognostication in small (pT1) breast cancers by image cytometry.

Authors:  M Aubele; G Auer; U Falkmer; A Voss; K Rodenacker; L E Rutquist; H Höfler
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG. (Eastern Cooperative Oncology Group).

Authors:  K W Gilchrist; R Gray; A M van Driel-Kulker; W E Mesker; J J Ploem-Zaaijer; J S Ploem; S G Taylor; D C Tormey
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

7.  The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer.

Authors:  Selma Yildirim-Assaf; Alexandra Coumbos; Werner Hopfenmüller; Hans-Dieter Foss; Harald Stein; Wolfgang Kühn
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

8.  The relationship of estrogen receptor status to DNA ploidy in breast cancer.

Authors:  A Tsuchiya; M Nihei; Y Ando; S Suzuki; I Kimijima; R Abe
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.